Molecular Mechanisms Underlying Vascular Liver Diseases: Focus on Thrombosis

Vascular liver disorders (VLDs) comprise a wide spectrum of clinical-pathological entities that primarily affect the hepatic vascular system of both cirrhotic and non-cirrhotic patients. VLDs more frequently involve the portal and the hepatic veins, as well as liver sinusoids, resulting in an imbalance of liver homeostasis with serious consequences, such as the development of portal hypertension and liver fibrosis. Surprisingly, many VLDs are characterized by a prothrombotic phenotype. The molecular mechanisms that cause thrombosis in VLD are only partially explained by the alteration in the Virchow's triad (hypercoagulability, blood stasis, and endothelial damage) and nowadays their pathogenesis is incompletely described and understood. Studies about this topic have been hampered by the low incidence of VLDs in the general population and by the absence of suitable animal models. Recently, the role of coagulation imbalance in liver disease has been postulated as one of the main mechanisms linked to fibrogenesis, so a novel interest in vascular alterations of the liver has been renewed. This review provides a detailed analysis of the current knowledge of molecular mechanisms of VLD. We also focus on the promising role of anticoagulation as a strategy to prevent liver complications and to improve the outcome of these patients.

[1]  L. Carbonaro,et al.  Focal Liver Lesions in Budd-Chiari Syndrome: Spectrum of Imaging Findings , 2023, Diagnostics.

[2]  A. Gasbarrini,et al.  Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications , 2023, Cells.

[3]  J. Ampuero,et al.  Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial , 2023, Journal of Hepatology.

[4]  J. García‐Pagán,et al.  Primary Budd-Chiari Syndrome. , 2023, The New England journal of medicine.

[5]  C. Diaconu,et al.  Budd-Chiari syndrome in myeloproliferative neoplasms: A review of literature , 2023, World journal of clinical oncology.

[6]  S. Chevret,et al.  Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis. , 2023, Journal of hepatology.

[7]  M. Giuffré,et al.  Pylephlebitis: A Systematic Review on Etiology, Diagnosis, and Treatment of Infective Portal Vein Thrombosis , 2023, Diagnostics.

[8]  Samar H. Ibrahim,et al.  The evolving role of liver sinusoidal endothelial cells in liver health and disease. , 2023, Hepatology.

[9]  M. Ronot,et al.  Management of splanchnic vein thrombosis , 2023, JHEP reports : innovation in hepatology.

[10]  A. Gasbarrini,et al.  From coagulation imbalance to prediction of advanced chronic liver disease decompensation: the wind of change? , 2023, Journal of hepatology.

[11]  Won-Mook Choi,et al.  Porto-Sinusoidal Vascular Disease: A Concise Updated Summary of Epidemiology, Pathophysiology, Imaging, Clinical Features, and Treatments , 2023, Korean journal of radiology.

[12]  Zongli Zhang,et al.  Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis , 2022, Frontiers in Oncology.

[13]  V. Vilgrain,et al.  Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis , 2022, NEJM Evidence.

[14]  A. Gasbarrini,et al.  Low ADAMTS-13/VWF ratio and altered gut–liver axis predict complications of advanced chronic liver disease: a pilot study , 2022, Gastroenterology report.

[15]  A. Mullally,et al.  Molecular Pathogenesis of Myeloproliferative Neoplasms , 2022, Current Hematologic Malignancy Reports.

[16]  Dhir Gala,et al.  Thromboembolic Events in Patients with Inflammatory Bowel Disease: A Comprehensive Overview , 2022, Diseases.

[17]  M. Jovanović,et al.  Suppurative Thrombosis of the Portal Vein (Pylephlebits): A Systematic Review of Literature , 2022, Journal of clinical medicine.

[18]  E. Chouery,et al.  Genetic predisposition to porto‐sinusoidal vascular disorder: A functional genomic‐based, multigenerational family study , 2022, Hepatology.

[19]  F. Ponziani,et al.  ADAMTS-13/von Willebrand factor ratio: A prognostic biomarker for portavein thrombosis in compensated cirrhosis. A prospective observational study. , 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[20]  C. Sempoux,et al.  Porto-sinusoidal vascular disorder. , 2022, Journal of hepatology.

[21]  E. Yoshida,et al.  Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis. , 2022, European journal of internal medicine.

[22]  Tamara Milovanovic,et al.  Celiac Disease and Thrombotic Events: Systematic Review of Published Cases , 2022, Nutrients.

[23]  V. de Lédinghen,et al.  Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications , 2022 .

[24]  H. Yoshiji,et al.  ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability , 2022, Journal of clinical medicine.

[25]  M. Trauner,et al.  Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. , 2022, Journal of hepatology.

[26]  A. Falanga,et al.  Thrombosis in myeloproliferative neoplasms: A clinical and pathophysiological perspective , 2021, Thrombosis Update.

[27]  H. Yoshiji,et al.  Baveno VII - Renewing consensus in portal hypertension. , 2021, Journal of hepatology.

[28]  F. Depasse,et al.  Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine , 2021, Journal of thrombosis and haemostasis : JTH.

[29]  R. Borrás,et al.  Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. , 2021, Journal of hepatology.

[30]  M. Juan,et al.  Autoimmune biomarkers in porto‐sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[31]  J. Lozano,et al.  Coexpression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease. , 2021, Journal of hepatology.

[32]  Shuang Han,et al.  mTOR regulates GPVI-mediated platelet activation , 2021, Journal of Translational Medicine.

[33]  L. Goldfinger,et al.  Platelets and extracellular vesicles and their cross-talk with cancer. , 2021, Blood.

[34]  Jian-Bo Han,et al.  Predictive Value of Inflammation Biomarkers in Patients with Portal Vein Thrombosis , 2021, Journal of clinical and translational hepatology.

[35]  T. Hilberg,et al.  Sport and Venous Thromboembolism Site, Accompanying Features, Symptoms, and Diagnosis. , 2021, Deutsches Arzteblatt international.

[36]  C. James,et al.  Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms , 2021, Leukemia.

[37]  R. Francés,et al.  Role of liver sinusoidal endothelial cells in liver diseases , 2021, Nature Reviews Gastroenterology & Hepatology.

[38]  Jing Zhang,et al.  Evaluation of Coagulation, Fibrinolysis and Endothelial Biomarkers in Cirrhotic Patients With or Without Portal Venous Thrombosis , 2020, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[39]  Shi-yao Chen,et al.  Effects of Anticoagulants on Experimental Models of Established Chronic Liver Diseases: A Systematic Review and Meta-Analysis , 2020, Canadian journal of gastroenterology & hepatology.

[40]  R. Hoffman,et al.  Clinical Insights into the Origins of Thrombosis in Myeloproliferative Neoplasms. , 2020, Blood.

[41]  J. Crespo,et al.  Portal Thrombosis in Cirrhosis: Role of Thrombophilic Disorders , 2020, Journal of clinical medicine.

[42]  P. D. de Groot,et al.  Interplay between platelets and coagulation , 2020, Blood Reviews.

[43]  Xiaoquan Huang,et al.  Increased portal vein diameter is predictive of portal vein thrombosis development in patients with liver cirrhosis , 2020, Annals of translational medicine.

[44]  F. Violi,et al.  Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced Liver Disease: An Exploratory Meta‐Analysis , 2020, Hepatology communications.

[45]  P. Reese,et al.  Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation , 2020, Hepatology.

[46]  Bao-yan Xu,et al.  Prevalence and Clinical Significance of Portal Vein Thrombosis in Patients with Cirrhosis and Acute Decompensation. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[47]  J. Trebicka,et al.  Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis , 2020, Clinical and translational gastroenterology.

[48]  V. Patel,et al.  Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay , 2020, Journal of thrombosis and haemostasis : JTH.

[49]  H. You,et al.  [Clinical features and risk factors of portal vein thrombosis in 28 patients with antiphospholipid syndrome]. , 2019, Zhonghua nei ke za zhi.

[50]  S. Llerena,et al.  Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It , 2019, Cells.

[51]  T. Schiano,et al.  Idiopathic noncirrhotic portal hypertension. , 2019, Seminars in diagnostic pathology.

[52]  A. de Gottardi,et al.  Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. , 2019, Journal of hepatology.

[53]  S. Caldwell,et al.  Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. , 2019, Gastroenterology.

[54]  V. Vilgrain,et al.  Porto-sinusoidal vascular disease: proposal and description of a novel entity. , 2019, The lancet. Gastroenterology & hepatology.

[55]  M. Armstrong,et al.  Review article: a multidisciplinary approach to the diagnosis and management of Budd‐Chiari syndrome , 2019, Alimentary pharmacology & therapeutics.

[56]  D. Valla,et al.  Nonselective beta‐blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study , 2019, Alimentary pharmacology & therapeutics.

[57]  C. Mulder,et al.  Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[58]  Z. Sparchez,et al.  Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis , 2018, The American Journal of Gastroenterology.

[59]  T. Barbui,et al.  JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis , 2018, Blood Cancer Journal.

[60]  C. Sempoux,et al.  Histology of portal vascular changes associated with idiopathic non‐cirrhotic portal hypertension: nomenclature and definition , 2018, Histopathology.

[61]  S. Sarin,et al.  Budd–Chiari syndrome: a focussed and collaborative approach , 2018, Hepatology International.

[62]  Han‐Chieh Lin,et al.  Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats , 2018, Digestive Diseases and Sciences.

[63]  C. Denis,et al.  Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression , 2018, Haematologica.

[64]  V. Vanneaux,et al.  Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features , 2018, Thrombosis and Haemostasis.

[65]  P. Poredos,et al.  Endothelial Dysfunction and Venous Thrombosis , 2018, Angiology.

[66]  M. Ronot,et al.  Diagnosis of Budd–Chiari syndrome , 2018, Abdominal Radiology.

[67]  N. Leeper,et al.  Thrombotic Regulation From the Endothelial Cell Perspectives. , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[68]  A. Lebreton,et al.  Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis , 2018, Journal of thrombosis and haemostasis : JTH.

[69]  D. Sacchi,et al.  Pathology of idiopathic non-cirrhotic portal hypertension , 2018, Virchows Archiv.

[70]  D. Bauer,et al.  Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity , 2018, Alimentary pharmacology & therapeutics.

[71]  D. Valla Budd–Chiari syndrome/hepatic venous outflow tract obstruction , 2018, Hepatology International.

[72]  M. Merli,et al.  Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis. , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[73]  S. Caldwell,et al.  Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case‐control study , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[74]  M. Moia,et al.  Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[75]  D. Colomer,et al.  Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. , 2017, Journal of hepatology.

[76]  T. Roskams,et al.  Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[77]  R. Porte,et al.  Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases , 2017, Research and practice in thrombosis and haemostasis.

[78]  M. Avila,et al.  The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells , 2017, Hepatology.

[79]  A. de Gottardi,et al.  Antithrombotic treatment with direct‐acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[80]  T. Deloughery,et al.  The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis , 2017, European journal of haematology.

[81]  J. How,et al.  Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease , 2017, Therapeutic advances in hematology.

[82]  F. Pomero,et al.  Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome , 2017, Thrombosis and Haemostasis.

[83]  P. Mannucci,et al.  Changing Concepts of Cirrhotic Coagulopathy , 2017, The American Journal of Gastroenterology.

[84]  S. Basili,et al.  Low‐grade endotoxemia and platelet activation in cirrhosis , 2017, Hepatology.

[85]  S. Middeldorp Inherited thrombophilia: a double-edged sword. , 2016, Hematology. American Society of Hematology. Education Program.

[86]  V. Novakovic,et al.  Phosphatidylserine on blood cells and endothelial cells contributes to the hypercoagulable state in cirrhosis , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[87]  C. Colak,et al.  Incidence and clinical presentation of portal vein thrombosis in cirrhotic patients. , 2016, Hepatobiliary & pancreatic diseases international : HBPD INT.

[88]  L. Christou,et al.  High von Willebrand factor antigen levels and procoagulant imbalance may be involved in both increasing severity of cirrhosis and portal vein thrombosis , 2016, Hepatology.

[89]  P. Kamath,et al.  Toward a Comprehensive New Classification of Portal Vein Thrombosis in Patients With Cirrhosis. , 2016, Gastroenterology.

[90]  L. Santambrogio,et al.  Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo. , 2016, Blood.

[91]  D. Valla,et al.  Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension , 2016, Hepatology.

[92]  M. Pompili,et al.  Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study , 2016, Internal and Emergency Medicine.

[93]  A. Farcomeni,et al.  Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry , 2016, Internal and Emergency Medicine.

[94]  L. Giacomelli,et al.  Obliterative portal venopathy without portal hypertension: an underestimated condition , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[95]  M. Sakayori,et al.  Trousseau's syndrome: cancer-associated thrombosis. , 2016, Japanese journal of clinical oncology.

[96]  S. Caldwell,et al.  Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation , 2016, Digestive Diseases and Sciences.

[97]  D. Fan,et al.  Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis , 2016, European journal of gastroenterology & hepatology.

[98]  A. Tefferi,et al.  Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors , 2015, Blood Cancer Journal.

[99]  S. Verma,et al.  Endothelial cell control of thrombosis , 2015, BMC Cardiovascular Disorders.

[100]  M. Hashizume,et al.  Comprehensive Screening of Gene Function and Networks by DNA Microarray Analysis in Japanese Patients with Idiopathic Portal Hypertension , 2015, Mediators of inflammation.

[101]  L. Pasta,et al.  Thrombophilic genetic factors PAI-1 4G-4G and MTHFR 677TT as risk factors of alcohol, cryptogenic liver cirrhosis and portal vein thrombosis, in a Caucasian population. , 2015, Gene.

[102]  A. Franco,et al.  Platelets at the interface of thrombosis, inflammation, and cancer. , 2015, Blood.

[103]  F. Leebeek,et al.  The Fibrinolytic Status in Liver Diseases , 2015, Seminars in Thrombosis & Hemostasis.

[104]  J. Verheij,et al.  Idiopathic non-cirrhotic portal hypertension: a review , 2015, Orphanet Journal of Rare Diseases.

[105]  A. Tawfik,et al.  De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system , 2015, European journal of gastroenterology & hepatology.

[106]  R. Groszmann,et al.  Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. , 2015, Journal of hepatology.

[107]  O. Christophe,et al.  von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. , 2015, Blood.

[108]  D. Valla,et al.  Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis , 2015, Haematologica.

[109]  S. Chevret,et al.  Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study , 2015, Hepatology.

[110]  Baljendra Kapoor,et al.  Diagnosis and Management of Budd Chiari Syndrome: An Update , 2015, CardioVascular and Interventional Radiology.

[111]  D. Fan,et al.  Associations of Antiphospholipid Antibodies With Splanchnic Vein Thrombosis , 2015, Medicine.

[112]  D. Schuppan,et al.  Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. , 2014, Gastroenterology.

[113]  Jin-Wook Kim,et al.  Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis , 2014, Clinical and molecular hepatology.

[114]  D. Fan,et al.  Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[115]  R. Porte,et al.  Thrombomodulin-modified thrombin generation testing detects a hypercoagulable state in patients with cirrhosis regardless of the exact experimental conditions. , 2014, Thrombosis research.

[116]  A. Berzigotti,et al.  Idiopathic portal hypertension: Natural history and long‐term outcome , 2014, Hepatology.

[117]  O. Riggio,et al.  Idiopathic Non Cirrhotic Portal Hypertension and Spleno-Portal Axis Abnormalities in Patients with Severe Primary Antibody Deficiencies , 2014, Journal of immunology research.

[118]  K. Peerlinck,et al.  Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII , 2014, Journal of thrombosis and haemostasis : JTH.

[119]  C. Musumba Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy , 2013, Alimentary pharmacology & therapeutics.

[120]  Q. Jiang,et al.  Clinical and pathological features and surgical treatment of Budd‐Chiari syndrome‐associated hepatocellular carcinoma , 2013, Chinese medical journal.

[121]  Víctor M. Navarro,et al.  Common Variable Immunodeficiency Causing Non-cirrhotic Portal Hypertension: Case Report and a Review of Literature: 1188 , 2013 .

[122]  V. Ertekin,et al.  Hepatoportal Sclerosis in Childhood: Descriptive Analysis of 12 Patients , 2013, Journal of Korean medical science.

[123]  P. Mannucci,et al.  Global coagulation in myeloproliferative neoplasms , 2013, Annals of Hematology.

[124]  D. Valla,et al.  Behcet’s disease in budd-chiari syndrome , 2013, Orphanet Journal of Rare Diseases.

[125]  M. De Grandis,et al.  JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. , 2013, Blood.

[126]  D. Valla,et al.  Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. , 2012, Blood.

[127]  M. Hashizume,et al.  Prognostic factors in patients with idiopathic portal hypertension: Two Japanese nationwide epidemiological surveys in 1999 and 2005 , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

[128]  J. Schouten,et al.  Risk factors and outcome of HIV‐associated idiopathic noncirrhotic portal hypertension , 2012, Alimentary pharmacology & therapeutics.

[129]  Zhenpeng Qiu,et al.  Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin‐induced apoptosis by inhibiting p53 activation , 2012, Hepatology.

[130]  D. Valla,et al.  Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. , 2012, Gastroenterology.

[131]  A. Gasbarrini,et al.  What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective. , 2012, World journal of gastroenterology.

[132]  P. Simioni,et al.  Increased anticoagulant response to low‐molecular‐weight heparin in plasma from patients with advanced cirrhosis , 2012, Journal of thrombosis and haemostasis : JTH.

[133]  J. García‐Pagán,et al.  Functional aspects on the pathophysiology of portal hypertension in cirrhosis. , 2012, Journal of hepatology.

[134]  B. Şahın,et al.  Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis , 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[135]  T. Roskams,et al.  Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long‐term cohort study , 2012, Alimentary pharmacology & therapeutics.

[136]  P. Mannucci,et al.  Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma , 2012, Internal and Emergency Medicine.

[137]  Y. Iwakiri Endothelial dysfunction in the regulation of cirrhosis and portal hypertension , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[138]  V. Brancaccio,et al.  Antiphospholipid Antibodies and Antiphospholipid Syndrome: Role in Portal Vein Thrombosis in Patients With and Without Liver Cirrhosis , 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[139]  T. Cenci,et al.  Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. , 2011, Blood.

[140]  P. Vanhems,et al.  The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study. , 2011, Journal of hepatology.

[141]  F. Leebeek,et al.  Hypercoagulability and Hypofibrinolysis and Risk of Deep Vein Thrombosis and Splanchnic Vein Thrombosis: Similarities and Differences , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[142]  V. Paradis,et al.  Obliterative portal venopathy: portal hypertension is not always present at diagnosis. , 2011, Journal of hepatology.

[143]  G. Gerken,et al.  Low‐molecular‐weight heparin in patients with advanced cirrhosis , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[144]  A. Bergquist,et al.  The epidemiology and clinical features of portal vein thrombosis: a multicentre study , 2010, Alimentary pharmacology & therapeutics.

[145]  Mercedes Fernandez,et al.  Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. , 2010, Journal of hepatology.

[146]  P. Mannucci,et al.  Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method , 2010, Hepatology.

[147]  S. Ahn,et al.  [Deficiencies in proteins C and S in a patient with idiopathic portal hypertension accompanied by portal vein thrombosis]. , 2010, The Korean journal of hepatology.

[148]  V. Soriano,et al.  Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings , 2010, AIDS.

[149]  P. Mannucci,et al.  An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. , 2009, Gastroenterology.

[150]  S. Chanock,et al.  A Spectrum of Severe Familial Liver Disorders Associate with Telomerase Mutations , 2009, PloS one.

[151]  A. Gasbarrini,et al.  Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. , 2009, Journal of hepatology.

[152]  F. Rosendaal,et al.  Etiology, management, and outcome of the Budd-Chiari syndrome. , 2009, Annals of internal medicine.

[153]  T. Schiano,et al.  The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. , 2009, Blood.

[154]  T. Barbui,et al.  Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. , 2008, Blood.

[155]  S. Chevret,et al.  The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. , 2008, Blood.

[156]  M. Gianni,et al.  Inherited thrombophilic abnormalities and risk of portal vein thrombosis , 2008, Thrombosis and Haemostasis.

[157]  Mercedes Fernandez,et al.  Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability , 2007, Hepatology.

[158]  G. Tiscia,et al.  A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. , 2007, Blood.

[159]  R. Jalan,et al.  The puzzle of endothelial nitric oxide synthase dysfunction in portal hypertension: The missing piece? , 2007, Hepatology.

[160]  N. Enomoto,et al.  Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. , 2007, Journal of hepatology.

[161]  M. Björck,et al.  Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. , 2006, World journal of gastroenterology.

[162]  Toshio Mori,et al.  Localization of ADAMTS13 to the stellate cells of human liver. , 2005, Blood.

[163]  C. Yurdaydın,et al.  Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis , 2005, European journal of gastroenterology & hepatology.

[164]  A. Tripodi,et al.  LIVER FAILURE AND LIVER DISEASE , 2005 .

[165]  N. Mackman Role of tissue factor in hemostasis, thrombosis, and vascular development. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[166]  Y. Okada,et al.  Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. , 2004, Biochemical and biophysical research communications.

[167]  D. Valla,et al.  Vascular involvement of the liver in Turner's syndrome , 2004, Hepatology.

[168]  T. Hamamoto,et al.  A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? , 2001, Journal of biochemistry.

[169]  L. Blendis,et al.  Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension , 1995, Hepatology.

[170]  M. Omata,et al.  Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits. , 1988, Gastroenterology.

[171]  S. Sarin,et al.  Familial aggregation in noncirrhotic portal fibrosis: a report of four families. , 1987, The American journal of gastroenterology.

[172]  K. Okuda,et al.  Splanchnic hemodynamics in portal hypertensive dogs with portal fibrosis. , 1987, The American journal of physiology.

[173]  A. Falanga,et al.  Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. , 1985, Biochemistry.

[174]  D. Valla,et al.  EASL Clinical Practice Guidelines: Vascular diseases of the liver. , 2016, Journal of hepatology.

[175]  Akie Hirata,et al.  Idiopathic portal hypertension in a patient with mixed connective tissue disease and protein C deficiency. , 2010, Internal medicine.

[176]  D. Valla Primary Budd-Chiari syndrome. , 2009, Journal of hepatology.

[177]  H. Janssen,et al.  Vascular liver disorders (II): portal vein thrombosis. , 2009, The Netherlands journal of medicine.

[178]  N. Hassan,et al.  A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat. , 2005, Pharmacological research.

[179]  A. Bernardo,et al.  Hemostasis, Thrombosis, and Vascular Biology , 2022 .

[180]  K. Rák,et al.  Endothelium releases more von Willebrand factor and tissue-type plasminogen activator upon venous occlusion in patients with liver cirrhosis than in normals. , 1993, Haemostasis.